Systemic sclerosis and dexamethasone cyclophosphamide pulse therapy
نویسندگان
چکیده
منابع مشابه
Systemic sclerosis and dexamethasone cyclophosphamide pulse therapy.
Sir, There have been quite a few instances where the physician or may be even a dermatologist (mis) advices a patient having systemic sclerosis that there is no satisfactory treatment for this disease, as has also been done in the paper Therapeutic trials for systemic sclerosis: An update by Sardana and Garg.[1] Such patients often feel frustrated and disappointed, till another dermatologist ...
متن کاملDexamethasone-cyclophosphamide pulse therapy in pemphigus.
Fifty patients with pemphigus (45 pemphigus vulgaris, 5 pemphigus foliaceus) were treated with dexamethasone-cyclophosphamide pulse therapy. The pulse consisted of 136 mg dexamethasone dissolved in 5% dextrose given in a drip over a period of 1-2 hours on 3 consecutive days. In addition, 500 mg cyclophosphamide was added in the drip on the first day. Such pulses were given at monthly intervals....
متن کاملDexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus: a case report.
OBJECTIVE To put systemic lupus erythematosus (SLE) in remission for a prolonged period. METHODS Dexamethasone cyclophosphamide pulse (DCP) therapy was used in a 40-year-old female with SLE of 3 years' duration. DCP therapy comprises an intravenous infusion of 100 mg dexamethasone in 500 ml of 5% glucose over 1-1(1/2) hours on 3 consecutive days along with cyclophosphamide 500 mg in the same ...
متن کاملDexamethasone cyclophosphamide pulse therapy: some suggestions for modifications.
Sir, It was truly enlightening and educative reading the editorial on dexamethasone pulse therapy in dermatology and the associated viewpoint by Prof. Pasricha who is widely regarded as the father of pulse therapy in India. Pulse therapy has altered the management and outcome of autoimmune diseases in general and pemphigus in particular. It has slowly but surely replaced the conventional dosing...
متن کاملCyclophosphamide in systemic sclerosis: light and shadows.
© Copyright CLINICALAND EXPERIMENTAL RHEUMATOLOGY 2004. Pulmonary interstitial fibrosis (PIF) affects half of all patients with systemic sclerosis (SSc) (1) and accounts for one-third of SSc-related deaths (2). Despite enormous efforts, therapy remains empirical and its efficacy is questionable. D-penicillamine (3) interfero n -γ (4), and cyclophosphamide (5) have been used to halt the progress...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Dermatology, Venereology and Leprology
سال: 2009
ISSN: 0378-6323
DOI: 10.4103/0378-6323.55399